Market News

Merck and Bayer's heart drug meets main goal of late-stage study

Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study. The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients with worsening chronic heart failure compared to placebo, when given in combination with available therapies for the condition, Merck said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Sam

Gulfport Energy to halt share buybacks, slash jobs-sources

U.S. gas exploration and production company Gulfport Energy Corp will announce job cuts, board changes and an end to its share buybacks on Monday, in a bid to reverse a slide in its share price, according to people familiar with the matter.


Billionaires' wealth falls for first time since 2015

The world's richest people became a little less well off last year, according to a report by UBS and PwC, as geopolitical turmoil and volatile equity markets reduced the wealth of billionaires for...